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To hear Tom Cech tell it, he came
by his prodigious success — Nobel
Prize at 41, presidency of the
Howard Hughes Medical Institute
(HHMI) this year at 52 — thanks to
lots of help from his friends.
His 1982 discovery that RNA
could behave like an enzyme and
splice itself led to the 1989 Nobel in
chemistry, which he shared with
Sidney Altman. But he says he
stumbled into the RNA
World — then a small and
unfashionable one — pretty much by
accident. In 1978 he was studying a
DNA transcription unit in
Tetrahymena and, during the in vitro
transcription reaction, saw that RNA
splicing was also taking place.
At that time splicing had been
observed only in one other lab. The
finding was too good to ignore, so
Cech turned his attention to RNA.
“I was very fortunate that this small,
very tight-knit community, which
included John Abelson, Christine
Guthrie, Joan Steitz, and Jim
Dahlberg, among others, just
embraced me personally, and our
work. I was coming out of nowhere.
I didn’t have the credentials they
had — they’d all been to the MRC
in Cambridge and were already
famous scientists — and yet they
took us in right away and gave us
good advice and supported us.”
Thanks in part to Cech’s subsequent
discoveries, RNA is now viewed as
DNA’s ancestral molecule and a
trendy research topic, and the RNA
World is no longer small.
HHMI investigators, which
number around 350 top US
biomedical scientists, are not
grantees, they are employees.
Hughes writes generous checks to
support their labs, their equipment,
and their staff. Cech had been a
Hughes investigator at the
University of Colorado at Boulder
for more than a decade when he
was selected in 1999 to shepherd
one of the world’s largest biomedical
research organizations into the
next millennium.
“I had almost no qualifications for
this job at all,” he says. Cech now
heads a headquarters staff of about
300; only a few are scientists. He
spends most of his days at the
imposing new HHMI edifice in
Chevy Chase, an exceedingly
upscale Washington suburb not far
from the National Institutes of
Health campus in Bethesda,
Maryland. Those days are filled with
meetings — meetings with
accountants and purchasing people
and lawyers and the human resources
department. Not to mention the
people who supervise the Hughes
investments that make its legendary
largesse possible. The endowment
now stands comfortably above
$13 billion and counting, more than
the Ford Foundation, more even
than the gross domestic product of
several nations.
It is, he points out, far more like
running a big corporation than a lab.
How has he managed to get his
footing on such unfamiliar turf? Once
again, others have come to his aid.
“One thing that has helped me a lot
is the quality of the people here at
headquarters, very bright hard-
working people with good ideas.
I inherited a very functional staff
here from Purnell Choppin, the
previous president, who did a
marvelous job of building this group
of people,” he says. A big part of his
job is to keep them excited about
“doing work in support of some of
the most innovative science and
science education that’s being carried
out in the world today.”
When scientists move into
administration, they often vow to
retain their labs. Cech is among
them, jetting back to Boulder for a
week or two every month to stay
abreast of his colleagues’
investigations of RNA catalysis and
telomeres. While it may be useful for
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Prodigious success: Nobel prizewinner Tom Cech, new president of the Howard Hughes
Medical Institute in Washington.
the head of a huge medical research
organization to keep one foot in the
lab, the schedule is punishing. Guess
how he manages? “It’s possible
because I have a really great staff in
Colorado, a number of permanent
employees.” Chief among them is
Art Zaug, his associate of 20 years.
“Art really does a lot in terms of
looking over data and the day-to-day
troubleshooting of experiments. If it
weren’t for him I think this would be
quite a difficult balancing act.”
When Cech arrived at HHMI
earlier this year he directed the staff
to put together three scenarios for
research funding based on whether
investments were flourishing, or flat,
or even in decline. The pessimistic
scenarios seem likely to gather dust;
Hughes is planning for continued
growth of between five and seven
per cent a year. Over the next five
years, that will amount to hundreds
of millions of dollars to spend on new
initiatives in computational biology
and what Cech calls “technologically
intensive biology.” Cech is close-
mouthed about the details, which are
to be formally announced late this
year or early in 2001.
The biggest change so far is that
HHMI is finally moving into
computational biology and
bioinformatics in a big way. Hughes
came late to the bioinformatics
revolution, although Cech says the
move was in the works before he
took the helm. In May HHMI hired
its first dozen computational
biologists and, Cech says, many more
are in the offing.
“A very substantial fraction of
biomedical research is going to be
taking place in front of computer
terminals,” Cech says. The major
research task now is to explore and
analyze the contents of the giant
databases generated by the various
genome projects. “New genes and
new functions for genes are being
found rapidly through computational
techniques. Many of us think we’re
just seeing the very beginning of
what’s going to be. People say this is
a revolution in biology, but I don’t
think they’ve seen it yet. The
revolution is going to come 10 or
20 years from now.”
At that point, he predicts, the
revolution will have moved from the
lab into the doctor’s office. “The
diagnosis of both cellular disease and
infectious disease is going to be
genomic based. We don’t quite see
the pathway by which we’re going to
get from where we are now to that
point 10 or 20 years from now, but I
would like Hughes to be breaking
the trail in terms of providing the
technology and the expertise that’s
going to make that happen.”
Many of us think we’re just seeing
the very beginning of what’s
going to be
Key to the HHMI strategy in
genomics and bioinformatics is Gerry
Rubin, the world-renowned
geneticist who headed the Drosophila
genome project at the University of
California at Berkeley. Rubin has
signed on as HHMI’s new vice-
president for biomedical research. It
was Rubin, Cech says, who pointed
out that universities were losing their
computational biologists to industry’s
irresistible salaries, often 300% or
400% higher. The HHMI labs are
now allowed to hire computational
biologists at market rates, and
investigators are reporting that this is
already transforming the way they
run their labs. It isn’t enough, Cech
notes, to stem the academic brain
drain nationwide. But if computer
people are convinced to remain at 50
major universities, he argues, they
will provide a critical mass for
training the next generation of
computational biologists.
“What we’re doing in the Hughes
labs is the small picture. The much
bigger picture is to try to do this
nationally. We’ve been talking about
ways we can disseminate technology
and computational expertise
throughout the whole American
biomedical research scene and even
internationally. That would be a new
role for HHMI.”
The plan is likely to involve
massive efforts at training to
supplement the highly successful —
but hugely oversubscribed — training
courses already going on at places
like Cold Spring Harbor. Cech hints
that some of this may involve the
World Wide Web. HHMI, he points
out, has also been building up a large
investment in the Web, including
virtual labs and demonstrations.
Hughes is also converting all its
grants management to a Web-based
system. The most recent Latin
American and Canadian
International Scholars Program was
an open Web-based application
procedure for researchers. Those
working outside the US are not
Hughes employees, but compete in a
more conventional grants program.
In the last decade HHMI has
allocated nearly $100 million to
almost 200 scientists in some 20
countries. The grants program also
includes several education projects
and accounts for about 20% of
HHMI’s research spending — which
has just been boosted to $667 million
for the fiscal year that began in
September 2000.
There has been talk that HHMI
might begin supporting embryonic
stem cell research. Cech is non-
commital on this point, but notes
that the just-released NIH
guidelines permit the NIH to fund
research using stem cells derived
from embryos from in vitro
fertilization clinics that would
otherwise be discarded. “We
certainly are hoping that there’s a
powerful resolution of this issue at a
national level, that the Congress and
the NIH can come to grips with the
tremendous potential of stem cell
research — both for understanding
how human biology works and also
for alleviation of human disease.”
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